These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 7545428

  • 1. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
    Jost LM, Jacky E, Dommann-Scherrer C, Honegger HP, Maurer R, Sauter C, Stahel RA.
    Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
    [Abstract] [Full Text] [Related]

  • 2. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F.
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [Abstract] [Full Text] [Related]

  • 3. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, Rubagotti A, Congiu AM, Centurioni R, Olivieri A, Tedeschi L, Vespignani M, Nati S, Soracco M, Porcellini A, Contu A, Guarnaccia C, Pescosta N, Majolino I, Spriano M, Vimercati R, Rossi E, Zambaldi G, Mangoni L, Rizzoli V.
    J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
    [Abstract] [Full Text] [Related]

  • 4. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M.
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [Abstract] [Full Text] [Related]

  • 5. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
    O'Reilly SE, Hoskins P, Klimo P, Connors JM.
    Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
    [Abstract] [Full Text] [Related]

  • 6. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [Abstract] [Full Text] [Related]

  • 7. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
    Dreiher J, Shpilberg O, Raanani P, Chetrit A, Ben-Bassat I.
    Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
    [Abstract] [Full Text] [Related]

  • 8. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
    Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ.
    Blood; 1995 Jul 15; 86(2):451-6. PubMed ID: 7541661
    [Abstract] [Full Text] [Related]

  • 9. Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
    Chen YC, Ho CL, Kao WY, Hwang JM, Sheu LF, Chao TY.
    Ann Hematol; 2001 Nov 15; 80(11):647-52. PubMed ID: 11757723
    [Abstract] [Full Text] [Related]

  • 10. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP.
    N Engl J Med; 1993 Apr 08; 328(14):1002-6. PubMed ID: 7680764
    [Abstract] [Full Text] [Related]

  • 11. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S.
    J Clin Oncol; 2003 Apr 01; 21(7):1255-62. PubMed ID: 12663712
    [Abstract] [Full Text] [Related]

  • 12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 13. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, Wittes RE, DeVita VT, Young RC.
    J Clin Oncol; 1994 Oct 01; 12(10):2153-9. PubMed ID: 7523607
    [Abstract] [Full Text] [Related]

  • 14. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar 01; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 15. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I.
    Bone Marrow Transplant; 1995 Apr 01; 15(4):549-55. PubMed ID: 7655380
    [Abstract] [Full Text] [Related]

  • 16. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP.
    Ann Oncol; 1994 Apr 01; 5 Suppl 2():91-5. PubMed ID: 7515652
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors.
    Pichert G, Peters J, Stahel RA, Dommann C, Joss R, Gebbers JO, Kroner T, Sulser H, Honegger HP, Maurer R.
    Ann Oncol; 1992 Sep 01; 3(8):645-9. PubMed ID: 1280460
    [Abstract] [Full Text] [Related]

  • 18. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW, Mead GM, Whitehouse JM.
    J Clin Oncol; 1991 Dec 01; 9(12):2202-9. PubMed ID: 1720454
    [Abstract] [Full Text] [Related]

  • 19. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma.
    Müller U, Stahel RA.
    Ann Oncol; 1993 May 01; 4(5):399-402. PubMed ID: 7688980
    [Abstract] [Full Text] [Related]

  • 20. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
    Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, Gallo E, Ambrosetti A, Tecchio C, Tarella C, Gabbas A, Gallamini A, Gargantini L, Pizzuti M, Fioritoni G, Gottin L, Rossi G, Lazzarino M, Menestrina F, Paulli M, Palestro M, Cabras MG, Di Vito F, Pizzolo G.
    Br J Cancer; 2004 Jan 26; 90(2):372-6. PubMed ID: 14735179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.